Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products, has completed patient enrollment in its upcoming clinical study of JW-100, its proprietary cannabidiol lotion formulation for the treatment of atopic dermatitis, or eczema. The study is designed to investigate the efficacy and safety of JW-100. JUPW enrolled 66 patients for the multi-center, double-blinded, placebo-controlled trial. Study participants will be randomly selected to receive one of three topical formulations, including a placebo, at least twice daily. Data from the study is expected in Q1 2021. “We are eager to see the results of this trial, and should JW-100 prove effective, we plan to use the data from this study to file an Investigational New Drug (‘IND’) application with the U.S. Food and Drug Administration,” said Jupiter CEO Brian John in the press release. “With the eczema market valued at more than $10 billion in 2020 and a high percentage of patients unsatisfied with their current treatments, we believe Jupiter will be well-positioned to capitalize on the opportunity with our CBD-based proprietary formulation.”
To view the full press release, visit https://ibn.fm/nUciT
About Jupiter Wellness Inc.
Jupiter Wellness is a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced, skin-care therapeutics address indications including eczema, burns, herpes cold sores and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skin-care products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For additional information about this company, please visit www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.